News | May 19, 2022
WHO validates Convidecia vaccine for Covid-19
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
The report has estimated 4.74 million deaths for India in 2020 and 2021,
Foundation S will incorporate as its cornerstone initiative the former Sanofi Espoir Foundation’s ‘My Child Matters’ program in childhood cancer
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
The report pointed out that in the process of treating Covid-19, there are promising data to suggest that TCM is beneficial in reducing the risk of progression from mild-to-moderate cases to severe Covid-19
Jamnagar’s contributions towards wellness will get a global identity with WHO’s Global Centre for Traditional Medicine
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
